Fairmount Healthcare Fund II sells $300m Oruka Therapeutics stock

Fairmount Healthcare Fund II L.P., a major Oruka Therapeutics shareholder, sold 3,553,410 shares on July 1, 2026 for $300.0M total at $84.43/share, after converting 42,641 Series B preferred shares into common stock for no cash. The stock subsequently rose to $93.29 near a 52-week high ($97.78), with InvestingPro flagging potential overvaluation. Analysts were broadly constructive—UBS raised its price target to $130 (Buy) ahead of 28-week efficacy data, H.C. Wainwright reiterated $120 (Buy), Piper Sandler reaffirmed $180 (Overweight) following an IL-23 license amendment that expands development areas.

Analysis

This is more a liquidity/positioning event than a fundamental one. A large holder monetizing into strength does not automatically mean the story is broken, but it does tell us the tape is being supported by expectations rather than cash-flow visibility; in names like ORKA, that makes marginal supply more dangerous because there is no earnings floor to absorb disappointment.

The key catalyst remains the next efficacy/durability checkpoint. In inflammatory/derm biotech, the rerating is driven less by the initial headline and more by whether benefit persists cleanly into later timepoints; if the data is merely “good,” the stock can de-rate quickly because investors are already paying for best-in-class optionality. AbbVie’s APGE move is supportive for the whole category, but it also raises the bar for ORKA: big pharma M&A interest validates the space, yet it narrows the window for merely adequate assets.

The contrarian risk is that consensus is treating analyst targets as quasi-fundamental value when they are really probability-weighted option marks. ORKA may be overowned by momentum-sensitive accounts after a 6x+ run, so a small miss in durability or safety can trigger an outsized air pocket over the next 1-3 months. If the upcoming readout materially beats expectations and preserves a clean safety profile, the upside can extend, but that is now a high bar rather than a base case.

Key Decisions for Investors

• Take profits or avoid initiating new longs in ORKA ahead of the next 28-week data window; reward/risk is poor after the run unless you have a strong edge on the readout.
• For event-driven exposure, buy ORKA put spreads into the catalyst to express a controlled downside view; thesis breaks if the data shows clear durability/safety outperformance versus prior endpoints.
• Pair trade: long ABBV / short ORKA over the next 1-3 months to own the validated, cash-generative beneficiary of category M&A while fading the higher-beta single-asset name.
• Set an alert to reassess ORKA only if the next clinical update shows materially better-than-expected durability or if a strategic transaction emerges; absent that, the stock is vulnerable to a sentiment reset.